Midori USA, Inc.

Midori USA, Inc. is a biotechnology company developing a platform that identifies glycans from natural food sugars. This enables the creation of novel glycan products and targeted eubiotics, designed to modulate the animal microbiome. Their scientific approach aims to enhance animal health and nutrition through precise biological optimization.

The company originated as a biotechnology start-up, driven by the insight that targeted animal microbiome modulation could significantly improve health outcomes. This vision fueled their development of glycan-based solutions. Royal DSM, a global science company, acquired the remaining 63.5% stake in Midori USA, Inc. on July 26, 2021, integrating its innovative platform.

Midori USA, Inc. serves the animal health and nutrition sector, providing advanced methods to improve animal well-being. The company's vision focuses on transforming animal health through scientific innovation, utilizing glycans to create effective nutritional strategies. They aspire to contribute to a healthier future for animals globally.

# High-Level Overview

Midori USA, Inc. is a biotechnology company that develops targeted eubiotics—specialized compounds that modulate animal gut microbiomes to improve health, nutrition, and sustainability in livestock farming.[3] The company pioneered a precision platform using glycans derived from natural food sugars to enhance how the gut microbiome functions in animals, leading to improved nutrient utilization and overall animal health.[3] Midori serves the poultry, swine, ruminant, and aquaculture sectors, addressing the dual challenge of improving farm economics while reducing environmental impact.[3] The company was acquired by Royal DSM in July 2021 for $63 million, becoming part of DSM's broader sustainable farming portfolio and enabling the launch of its first targeted glycan product, Symphiome™.[3][4]

# Origin Story

Midori was founded in 2011 and is based in Cambridge, Massachusetts.[2][3] The company emerged from cutting-edge research into animal microbiome science, developing a discovery platform that brings advanced biotechnology to health solutions across multiple animal farming sectors.[2] The acquisition by Royal DSM in 2021 marked a pivotal moment: DSM already owned 38.5% of Midori's shares and acquired the remaining stake to strengthen its sustainable farming capabilities.[3] This move positioned Midori's technology as a cornerstone of DSM's eubiotics portfolio, complementing DSM's earlier acquisition of Biomin (part of the Erber Group).[3]

# Core Differentiators

• Precision glycan platform: Midori's technology identifies and deploys specific glycans from natural food sugars to precisely target and modulate animal gut microbiome function, rather than using broad-spectrum approaches.[3]

• Proven efficacy: The glycans deliver consistent, measurable improvements in nutrient utilization from feed and overall animal health, directly improving farm economics.[3]

• Synergy with established infrastructure: As part of DSM, Midori benefits from integration with a major global nutrition and health company, accelerating commercialization and market reach.[3][4]

• First-to-market advantage: Symphiome™, the first targeted glycan product from this collaboration, represents a novel category in the eubiotic space.[3]

# Role in the Broader Tech Landscape

Midori operates at the intersection of precision biotechnology and sustainable agriculture—two critical trends reshaping global food systems. As regulatory pressure and consumer demand for sustainable farming intensify, companies that can improve both environmental impact and farm profitability address a genuine market need. Midori's acquisition by DSM reflects the consolidation of biotech innovation into larger nutrition companies seeking to differentiate through sustainability credentials. The company's work on animal microbiome modulation exemplifies how precision science is moving beyond human health into agricultural applications, creating competitive advantages for farming operations that adopt these technologies early.

# Quick Take & Future Outlook

Midori's integration into DSM positions it to scale rapidly across global livestock markets, where demand for sustainable and economically viable farming solutions continues to grow. The success of Symphiome™ and subsequent glycan products will likely determine whether this platform becomes an industry standard or remains a niche offering. As regulatory frameworks around sustainable farming tighten and feed costs remain volatile, precision microbiome solutions that demonstrably improve feed efficiency and animal health will become increasingly valuable to large-scale producers. Midori's future influence will depend on expanding its product pipeline and proving long-term ROI for farmers adopting its technologies.